Table 1.
Publication year
|
Cell source
|
Induction program
|
Pretransplantation procedure
|
Material(s)
|
Dose/concentration
|
Disease model
|
Experiment duration
|
Treatment effect
|
Ref.
|
2022 | Human | DMEM + 10% (FBS + P/S) | 3D culture | Fibrinogen, calcium chloride, and thrombin-like protein | 3 × 105 cells | Avulsion of spinal motor roots in rats | 12 wk | The transcription of TNF-α, IL-1β, IL-6, and IL-17 and the expression of anti-inflammatory cytokines (TGF-β, IL-4, IL-10, and IL-13) were increased; the animals in the reimplantation + 2D group showed the best functional recovery | [82] |
2021 | Human | α-MEM + 20% (FBS + P/S) | Collected and resuspended in GelMA-bFGF | 10% GFD in a CSM tube | 1 × 106 cells/mL | 15 mm defect of the sciatic nerve in rats | 12 wk | Cell based therapy repaired large gap defects in peripheral nerves; the differentiation of DPSCs into nerve cells and Schwann-like nerve cells and the formation of myelinated nerve fibers were observed | [98] |
2021 | Human | DMEM + 10% (FBS + P/S + NEAA) | NLCs differentiated from DPSCs | - | 1 × 105 NLCs | 10 mm sciatic nerve defect in athymic nude rats | 12 wk | Two weeks after transplantation, approximately 75% of the transplanted cells differentiated into platelet-derived growth factor receptor alpha + OPCs expressing p75NTRd; transplantation promoted axon growth and improved nerve function | [145] |
2021 | Human | α-MEM + 15% FBS | Exosome collection | - | 200 μg/100 μL | Mouse model of spinal cord injury | 4 wk | Inhibited the ROS-MAPK-NFκB P65 signaling pathway to reduce M1 macrophage polarization, suppress the inflammatory response, and alleviate neurological damage | [121] |
2020 | Human | DMEM + 20% (FBS + P/S) | Preparation of scaffold-free cell sheets by coculture with FGF2 | - | 2 × 106 cells/cell sheet | Rat model of facial nerve crush injury | 3 wk | Cell sheets promoted axonal regeneration and functional recovery through continuous delivery of neurotrophic factors such as BDNF and GDNF | [116] |
2020 | Human | α-MEM + 10% (FBS + P/S + NEAA) | Induction of DPSCs differentiation into N-DPSCs; induction of DPSCs differentiation into N-DPSCs | - | - | Rat model of sciatic nerve crush injury | 1 mo | Both DPSCs and N-DPSCs promoted peripheral nerve repair through the expression of neurotrophic factors such as NGF, BDNF, and GDNF; the nerve repair effect of N-DPSCs was longer lasting | [146] |
2019 | Human (children) | DMEM + 15% (FBS+P/S) | - | - | 5 × 105 cells in 4 μL DMEM | Unilateral facial nerve crush injury in rats | 6 wk | Immature DPSCs promoted nerve regeneration and the formation of new myelin; the expression of nerve growth factor and anti-inflammatory cytokines (IL-6 and IL-10) increased significantly 7 d after treatment, and there was a decrease in the levels of soluble proinflammatory factors such as IL-2, IL-4, TNF-α, and IFN-γ | [87] |
2019 | Human | - | Induction of DPSCs differentiation into nerve cells | A PDO-based cell carrier | 7.5 × 105 cells | 6 mm defect of the sciatic nerve in rats | 12 wk | Multiperforated PDO tubes were effective biomaterial carriers; delivery of DPSCs impacted the inflammatory environment and promoted nerve regeneration and functional recovery | [89] |
2018 | Human | - | Isolation of STRO-1+/c-Kit+/CD34+ cells | Collagen scaffolds | 5 × 105 cells/animal | 6 mm defect of the sciatic nerve in rats | 4 wk | Nerve fiber regeneration and myelination and many myelinated axons were observed; DPSCs grafted into the sciatic nerve defect expressed the typical Schwann cell marker S100B and were positive for human NeuN | [12] |
2018 | Human | ADMEM + 10% FBS | Differentiated into neuronal cells (DF-DPSCs) | A conduit made from a Lyoplant membrane | - | 7-8 mm defect of the sciatic nerve in rats | 12 wk | DPSCs relieved neuropathic pain and inhibited inflammation in rats earlier than DF-DPSCs; at 12 wk after the operation, the expression of pAMPK/SIRT1 in DF-DPSCs and DPSCs increased, the expression of proinflammatory cytokines decreased, and the expression of NFκB decreased | [81] |
2018 | Human | ADMEM + 10% (FBS + P/S) | Differentiation into cholinergic neurons by adding D609 | Biodegradable tubule and fibrin glue | 1 × 106 DF-chNs | 5 mm defect of the sciatic nerve in rats | 8 wk | Transplanted DF-chNs promoted motor nerve regeneration and axon growth and expressed nerve growth factor receptor (p75NGFR) | [61] |
2018 | Human | - | - | An absorbable hemostat filled with human DPCs containing 1% atelocollagen, fibronectin, and laminin | 3 × 105 cells | Crush injury of the sciatic nerve in rats | 2 wk | DPCs stimulated Schwann cell differentiation and promoted peripheral nerve regeneration | [114] |
2017 | Human | Standard: α-MEM + 10% (FBS + NEAA + P/S). Differentiation: Standard + forskolin + bFGF + PDGF-AA + HRG1-β | Differentiation into Schwann-like cells (d-hDPSCs) | NeuraWrap™ conduits | - | 15 mm defect of the sciatic nerve in rats | 8 wk | Growth of axons, myelinated nerve fibers, and blood vessels; DPSCs still exerted strong angiogenic effects after differentiating into Schwann-like cells | [102] |
2017 | Human | α-MEM + 15% (FBS + AA + P/S + NEAA) | - | Fibrin conduits | 2 × 106/20 μL | 10 mm defect of the sciatic nerve in rats | 2 wk | Promoted nerve and axon regeneration; the transplanted cells expressed BDNF near the cell body, and the expression level of caspase-3 decreased | [45] |
2017 | Human | ADMEM + 10% FBS | Induction of DPSCs differentiation into nerve cells | Fibrin glue scaffold and collagen tubulation | 1 × 106 cells | 5 mm defect of the sciatic nerve in rats | 12 wk | Both hDPSCs and DF-hDPSCs promoted nerve regeneration and functional recovery; they could directly differentiate into nerve cells or facilitate nerve cell differentiation | [99] |
2015 | Human | α-MEM + 10% (FBS + P/S/AmB) | Transfection with Olig2 gene via a tetracycline (Tet) inducible system | - | 2 × 105 cells | Mouse model of local sciatic nerve demyelination | 6 wk | Recovery of sciatic nerve function; DPSCs differentiated into oligodendrocyte progenitors, and specific markers of oligodendrocyte progenitors and oligodendrocytes were expressed | [108] |
2015 | Human | DMEM + 10% FBS | G-CSF-induced stem cell mobilization (mobilized DPSCs and MDPSCs) | Collagen conduits | 3.0 × 105 MDPSCs | 5 mm defect of the sciatic nerve in rats | 5 wk | MDPSCs secreted neurogenic/angiogenic factors and promoted peripheral nerve regeneration | [112] |
2015 | Human | Culture dishes containing essential medium (alpha modification) + 10% (FBS + P/S + amphotericin B) | Induction of DPSCs differentiation into OPCs by transfection with a plasmid containing the human Olig2 gene | 2 × 105 cells | Sciatic nerve demyelination in mice | 6 wk | DPSCs differentiated into OPCs, and transplantation promoted myelin sheath formation and peripheral nerve function recovery | [107] | |
2015 | Human | DMEM + b-ME; DMEM + 10% (FBS + RA); DMEM + 10% (FBS + FSK + b-FGF + PDGF + HRG) | Differentiation of hDPSCs into Schwann-like cells | Cells combined with a pulsed electromagnetic field (PEMF) | 1 × 106 cells/10 mL/rat | Crush injury of the peripheral nerve in rats | 3 wk | Schwann-like cells derived from DPSCs exhibited the characteristics of glial cells, expressing CD104, S100, GFAP, laminin, and p75NTR; application of a PEMF promoted peripheral nerve regeneration after cell transplantation | [147] |
2012 | Human | DMEM + 10% FBS | - | - | 1 × 106 cells | Rat spinal cord transection model | 8 wk | DPSCs promoted axonal growth, differentiated into oligodendrocytes to treat spinal cord injury, and protected the nerve by inhibiting apoptosis and paracrine signaling | [105] |
2018 | Human | α-MEM + 10% (FBS + NEAA + P/S) | Application of fresh medium containing vitamin C cells reached approximately 80% confluence | - | - | Patients diagnosed with a traumatized permanent incisor | 12 mo | HDPSCs transplantation promoted the regeneration of pulp tissue including neuronal tissue, and the neuron marker NeuN was expressed | [75] |
Human | PBS + P/S | Collection of hDPSCs aggregates | The root canals of human teeth | - | Immunocompromised mice | 8 wk | Dental pulp tissue containing sensory nerves and blood vessels regenerated after HDPSCs transplantation | ||
Human | α-MEM + 10% (FBS + NEAA + P/S) | - | - | 3 × 105 cells | Rats injected into the dorsal root ganglion | 2 mo | HDPSCs exhibited the morphology of neurons and expressed TRPV1 and TRPM8 | ||
Pig | PBS + P/S | Collection of hDPSCs aggregates | - | - | Permanent incisors of young female minipigs | 3 mo | Pig DPSCs resulted in the 3D regeneration of dental pulp with neural function | ||
2015 | Pig | Culture medium + 10% (FBS + L-AA -2-P + P/S) | - | Fibrin membrane | - | Porcine intercostal nerve transection model | 6 mo | DPSCs alleviated nerve injury and express NSE; neuroelectrophysiological evaluation showed that neurological function was restored | [88] |
2020 | Rat | α-MEM + 20% FBS | - | - | 1 × 106 cells/rat | Diabetic rats | 4 wk | Multiple factors secreted by DPSCs increased the nerve conduction velocity and blood flow to nerves | [118] |
2019 | Rat | α-MEM + glucose + 20% FBS | Collection of DPSCs-CM | - | 1 mL/rat | Diabetic rats | 4 wk | DPSCs-CM ameliorated peripheral neuropathy by exerting neuroprotective, angiogenic, and anti-inflammatory effects | [132] |
2017 | Rat | α-MEM + 20% FBS | - | - | 1 × 106 cells | Streptozotocin-induced diabetes rat model | 4 wk | Sensory disturbance was alleviated, the thickness and area of the myelin sheath increased, the transplanted DPSCs secreted multiple factors such as angiogenic factors, neurotrophic factors, and immunosuppressive factors | [84] |
2015 | Rat | α-MEM + glucose + 20% FBS | - | - | 1 × 106 cells | Diabetic rats | 4 wk | DPSCs transplantation relieved diabetic polyneuropathy by inhibiting inflammation, exerting immunomodulatory effects, and secreting neurotrophic factors | [86] |
2015 | Rat | α-MEM + 20% FBS | - | - | 1 × 106 cells/limb | Diabetic rats | 8 wk | DPSCs increased the nerve conduction velocity and blood flow to nerves and promoted an increase in the number of nerve fibers in diabetic rats | [83] |
2013 | Rat | DMEM + 10% (FBS + P/S) | - | - | 1.5 × 105 cells | Crush injury of the optic nerve in rats | 3 wk | Transplantation of DPSCs significantly increased the survival rate of retinal ganglion cells in rats and promote axonal regeneration | [58] |
2007 | Rat | - | Embedded in 10 mL type I collagen gel | 10-mm silicone tube | 1 × 105 cells | 7 mm defect of the facial nerve in rats | 2 wk | Regeneration of axons, blood vessels, and Schwann cells; Tuj1-positive axons and S100-positive Schwann-like supportive cells were found in regenerated nerves | [91] |
2018 | Rabbit | DMEM + 10% FBS | Construction of an acellular nerve graft for nerve regeneration | Xenogenic acellular nerve matrix | 6 × 105 cells per graft | 10 mm defect of the sciatic nerve in rabbits | 3 mo | Regeneration of nerve space showed that acellular nerve grafts containing DPSCs treated with myroilysin had a strong neural induction effect | [148] |
AA: Ascorbic acid; AmB: Amphotericin B; ADMEM: Advanced Dulbecco’s modified Eagle medium; bFGF: Basic fibroblast growth factor; b-ME: Beta-mercaptoethanol; BG: Beta-glycerophosphate; Dex: Dexamethasone; CSM: Cellulose/soy protein isolate composite membrane; DPSCs-CM: DPSCs-conditioned medium; DMEM: Dulbecco’s modified Eagle medium; DF-chNs: Differentiated cholinergic neurons; DF-DPSCs: Neuronal cells differentiated from DPSCs; FSK: Forskolin; bD609: Tricyclodecane-9-yl-xanthogenate; FBS: Fetal bovine serum; G-CSF: Granulocyte-colony stimulating factor; GFD: 10% GelMA hydrogel, recombinant human basic fibroblast growth factor and DPSCs; HRG1-β: Heregulin-β-1; L-AA-2-P: L-ascorbic acid-2-phosphate; NGF: Nerve growth factor; N-DPSCs: Neural-induced DPSCs; NSE: Neuron-specific enolase; NEAA: Nonessential amino acids; NLCs: Neural lineage cells; OPCs: Oligodendrocyte progenitor cells; P/S: Penicillin and streptomycin; PDGF-AA: Platelet-derived growth factor AA; PBS: Phosphate-buffered saline; PDGF: Platelet-derived growth factor; RA: All-trans retinoic acid; TGNCs: Trigeminal ganglion neuronal cells; IL: Interleukin; TNF: Tumor necrosis factor; TGF: Transforming growth factor.